(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 January 2003 (16.01.2003)

PCT

162162

(10) International Publication Number
WO 03/004030 A1

(51) International Patent Classification[7]: A61K 31/485, 9/00, A61P 25/04

(21) International Application Number: PCT/US02/21396

(22) International Filing Date: 3 July 2002 (03.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/303,357	6 July 2001 (06.07.2001)	US
60/329,445	15 October 2001 (15.10.2001)	US
60/329,432	15 October 2001 (15.10.2001)	US
60/329,444	15 October 2001 (15.10.2001)	US

(71) Applicant: ENDO PHARMACEUTICALS, INC. [US/US], 100 Painters Drive, Chadds Ford, PA 19317 (US)

(72) Inventors: KAO, Haui-Hung, 137 Colony Lane, Syosset, NY 11791 (US). BAICHWAL, Anand, R., 5 Kendell Drive, Wappingers Falls, NY 12590 (US) MCCALL, Troy, 8861 Three Chimneys Drive East, Germantown, TN 38138 (US) LEE, David; 3209 Swarthmore Road, Wilmington, DE 19807 (US)

(74) Agents: DONATIELLO, Guy, T. et al., Schnader Harrison Segal & Lewis LLP, 1600 Market Street, Suite 3600, Philadelphia, PA 19103 (US)


(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:
- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

[Continued on next page]

(54) Title: OXYMORPHONE CONTROLLED RELEASE FORMULATIONS



(57) Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief

WO 03/004030 A1

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette